DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study's findings, which were presented at this year's AAO Annual Meeting.

In this month's business-focused episode, Melanie Denton Dombrowski, OD, MBA, FAAO, shares her first-hand experience on opening a practice cold (00:52), then Jessilin Quint, OD, MBA, MS, provides five tactics to sustain a practice's growth, success, and relevance (9:50). Jason E. Compton, OD, FAAO, follows with some great tips for developing a practice marketing plan (17:42), and Rachael Wruble, OD, FAAO, offers guidance on how to approach three common insurance and reimbursement problems (24:29).

Tracking real-world data on geographic atrophy has been patchwork process–until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group's findings to his practice. Dr. Rahimy presented data from this discussion during this year's AAO Annual Meeting Late Breakers session.

Settle in and listen to glaucoma specialist Lorraine Provencher, MD, and retina specialists Avni P. Finn, MD, MBA, and Christina Y. Weng, MD, MBA, navigate glaucoma and retina surgery for the cataract surgeon. These experts shed some light on proven strategies to further boost your confidence in the OR and share how to incorporate some of the major upgrades to glaucoma care seen in recent years, some of the best strategies for managing patients after complicated cataract surgery, and some of the top ways to maximize outcomes and select the appropriate IOL for retina patients. In this episode, these surgeons help to outline a blueprint for best practices in referring to and comanaging with glaucoma and retina specialists.

In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding-and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year's AAO Annual Meeting.

The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year's AAO Annual Meeting Late Breakers session.

In this special Thanksgiving episode of Ophthalmology Off the Grid, host Blake Williamson, MD, MPH, invites his colleagues to join him in expressing their gratitude. Hear from Dr. Williamson; Richard L. Lindstrom, MD; Evan Schoenberg, MD; Iqbal Ike K. Ahmed, MD, FRCSC; and Zaina Al-Mohtaseb, MD, on what has them feeling thankful in these particularly challenging times.

Gerami Seitzman, MD, Medical Director of the Francis I. Proctor Foundation at the University of California, San Francisco, shares how she and her colleagues developed a drive-through IOP screening service for patients whose care was interrupted by COVID-19, as featured in the September/October 2020 issue of Glaucoma Today.

In this podcast episode, Karolinne Rocha, MD, PhD*, and Elizabeth Yeu, MD, discuss the field of ocular biometry, including useful IOL power calculation formulas, as well as considerations taken for post-LASIK eyes and patients with astigmatism. They also review how they utilize the TECNIS SymfonyTM Extended Range of Vision IOLs (Johnson & Johnson Vision) for their patients.

*Drs. Karolinne Rocha and Elizabeth Yeu are paid consultants of Johnson & Johnson Surgical Vision, Inc.

Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year's AAO Annual Meeting.